Allergic rhinitis (AR) is a common condition characterized by symptoms like sneezing, nasal congestion, runny nose, and itchy eyes, typically triggered by allergens such as pollen, dust mites, or animal dander. Recent advances in therapy have significantly improved the management of AR, offering better symptom control and enhanced quality of life for patients. Traditional treatments, such as antihistamines, nasal corticosteroids, and decongestants, remain essential for many individuals. However, newer therapies are making a considerable impact. Immunotherapy, including sublingual and subcutaneous options, helps desensitize patients to allergens over time, providing long-term relief. Biologic treatments, such as monoclonal antibodies targeting specific inflammatory pathways (like IL-4, IL-5, or IL-13), have also emerged as promising options, particularly for severe cases. Additionally, advancements in precision medicine are allowing for more personalized approaches to treatment, taking into account the individual’s genetic and environmental factors. These innovations are helping to improve both short-term symptom relief and long-term management of allergic rhinitis.